Translocation carcinomas of the kidney after chemotherapy in childhood

Pedram Argani, Marick Laé, Edgar T. Ballard, Mahul Amin, Carlos Manivel, Brian Hutchinson, Victor E. Reuter, Marc Ladanyi

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Purpose: Children who survive cancer are at more than 19-fold increased risk of developing another malignancy. Renal cell carcinoma (RCC) occurring as a secondary malignancy is uncommon. Translocation RCC, bearing TFE3 or TFEB gene fusions, are recently recognized entities for which risk factors have not been identified. Patients and Methods: We describe the clinical, pathologic, cytogenetic, and molecular data on six translocation RCCs that arose in five young patients who had received chemotherapy. Results: The ages at time of diagnosis of the RCC ranged from 6 to 22 years. Histologically, these tumors showed typical features previously described for translocation RCCs. At the molecular level, three tumors contained the ASPL-TFE3 fusion, two contained Alpha-TFEB, and one contained PRCC-TFE3. The intervals between chemotherapy and the diagnosis of RCC ranged from 4 to 13 years. The indications for the antecedent chemotherapy were varied and included acute promyelocytic leukemia, acute myeloid leukemia with t(9;11), bilateral Wilms' tumor, systemic lupus erythematosus, and conditioning regimen of bone marrow transplant for Hurler's syndrome. Only the latter patient had also received radiation. Hence, among 39 genetically confirmed translocation RCCs in our personal experience, six (15%) have arisen in patients who had received cytotoxic chemotherapy. Conclusion: Cytotoxic chemotherapy may predispose to the development of renal translocation carcinomas.

Original languageEnglish (US)
Pages (from-to)1529-1534
Number of pages6
JournalJournal of Clinical Oncology
Volume24
Issue number10
DOIs
StatePublished - Apr 1 2006

Fingerprint

Renal Cell Carcinoma
Carcinoma
Kidney
Drug Therapy
Neoplasms
Mucopolysaccharidosis I
Acute Promyelocytic Leukemia
Wilms Tumor
Gene Fusion
Acute Myeloid Leukemia
Cytogenetics
Systemic Lupus Erythematosus
Bone Marrow
Radiation
Transplants

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Argani, P., Laé, M., Ballard, E. T., Amin, M., Manivel, C., Hutchinson, B., ... Ladanyi, M. (2006). Translocation carcinomas of the kidney after chemotherapy in childhood. Journal of Clinical Oncology, 24(10), 1529-1534. https://doi.org/10.1200/JCO.2005.04.4693

Translocation carcinomas of the kidney after chemotherapy in childhood. / Argani, Pedram; Laé, Marick; Ballard, Edgar T.; Amin, Mahul; Manivel, Carlos; Hutchinson, Brian; Reuter, Victor E.; Ladanyi, Marc.

In: Journal of Clinical Oncology, Vol. 24, No. 10, 01.04.2006, p. 1529-1534.

Research output: Contribution to journalArticle

Argani, P, Laé, M, Ballard, ET, Amin, M, Manivel, C, Hutchinson, B, Reuter, VE & Ladanyi, M 2006, 'Translocation carcinomas of the kidney after chemotherapy in childhood', Journal of Clinical Oncology, vol. 24, no. 10, pp. 1529-1534. https://doi.org/10.1200/JCO.2005.04.4693
Argani, Pedram ; Laé, Marick ; Ballard, Edgar T. ; Amin, Mahul ; Manivel, Carlos ; Hutchinson, Brian ; Reuter, Victor E. ; Ladanyi, Marc. / Translocation carcinomas of the kidney after chemotherapy in childhood. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 10. pp. 1529-1534.
@article{0b391d16b7f149f39fd23a33a2932f06,
title = "Translocation carcinomas of the kidney after chemotherapy in childhood",
abstract = "Purpose: Children who survive cancer are at more than 19-fold increased risk of developing another malignancy. Renal cell carcinoma (RCC) occurring as a secondary malignancy is uncommon. Translocation RCC, bearing TFE3 or TFEB gene fusions, are recently recognized entities for which risk factors have not been identified. Patients and Methods: We describe the clinical, pathologic, cytogenetic, and molecular data on six translocation RCCs that arose in five young patients who had received chemotherapy. Results: The ages at time of diagnosis of the RCC ranged from 6 to 22 years. Histologically, these tumors showed typical features previously described for translocation RCCs. At the molecular level, three tumors contained the ASPL-TFE3 fusion, two contained Alpha-TFEB, and one contained PRCC-TFE3. The intervals between chemotherapy and the diagnosis of RCC ranged from 4 to 13 years. The indications for the antecedent chemotherapy were varied and included acute promyelocytic leukemia, acute myeloid leukemia with t(9;11), bilateral Wilms' tumor, systemic lupus erythematosus, and conditioning regimen of bone marrow transplant for Hurler's syndrome. Only the latter patient had also received radiation. Hence, among 39 genetically confirmed translocation RCCs in our personal experience, six (15{\%}) have arisen in patients who had received cytotoxic chemotherapy. Conclusion: Cytotoxic chemotherapy may predispose to the development of renal translocation carcinomas.",
author = "Pedram Argani and Marick La{\'e} and Ballard, {Edgar T.} and Mahul Amin and Carlos Manivel and Brian Hutchinson and Reuter, {Victor E.} and Marc Ladanyi",
year = "2006",
month = "4",
day = "1",
doi = "10.1200/JCO.2005.04.4693",
language = "English (US)",
volume = "24",
pages = "1529--1534",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Translocation carcinomas of the kidney after chemotherapy in childhood

AU - Argani, Pedram

AU - Laé, Marick

AU - Ballard, Edgar T.

AU - Amin, Mahul

AU - Manivel, Carlos

AU - Hutchinson, Brian

AU - Reuter, Victor E.

AU - Ladanyi, Marc

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Purpose: Children who survive cancer are at more than 19-fold increased risk of developing another malignancy. Renal cell carcinoma (RCC) occurring as a secondary malignancy is uncommon. Translocation RCC, bearing TFE3 or TFEB gene fusions, are recently recognized entities for which risk factors have not been identified. Patients and Methods: We describe the clinical, pathologic, cytogenetic, and molecular data on six translocation RCCs that arose in five young patients who had received chemotherapy. Results: The ages at time of diagnosis of the RCC ranged from 6 to 22 years. Histologically, these tumors showed typical features previously described for translocation RCCs. At the molecular level, three tumors contained the ASPL-TFE3 fusion, two contained Alpha-TFEB, and one contained PRCC-TFE3. The intervals between chemotherapy and the diagnosis of RCC ranged from 4 to 13 years. The indications for the antecedent chemotherapy were varied and included acute promyelocytic leukemia, acute myeloid leukemia with t(9;11), bilateral Wilms' tumor, systemic lupus erythematosus, and conditioning regimen of bone marrow transplant for Hurler's syndrome. Only the latter patient had also received radiation. Hence, among 39 genetically confirmed translocation RCCs in our personal experience, six (15%) have arisen in patients who had received cytotoxic chemotherapy. Conclusion: Cytotoxic chemotherapy may predispose to the development of renal translocation carcinomas.

AB - Purpose: Children who survive cancer are at more than 19-fold increased risk of developing another malignancy. Renal cell carcinoma (RCC) occurring as a secondary malignancy is uncommon. Translocation RCC, bearing TFE3 or TFEB gene fusions, are recently recognized entities for which risk factors have not been identified. Patients and Methods: We describe the clinical, pathologic, cytogenetic, and molecular data on six translocation RCCs that arose in five young patients who had received chemotherapy. Results: The ages at time of diagnosis of the RCC ranged from 6 to 22 years. Histologically, these tumors showed typical features previously described for translocation RCCs. At the molecular level, three tumors contained the ASPL-TFE3 fusion, two contained Alpha-TFEB, and one contained PRCC-TFE3. The intervals between chemotherapy and the diagnosis of RCC ranged from 4 to 13 years. The indications for the antecedent chemotherapy were varied and included acute promyelocytic leukemia, acute myeloid leukemia with t(9;11), bilateral Wilms' tumor, systemic lupus erythematosus, and conditioning regimen of bone marrow transplant for Hurler's syndrome. Only the latter patient had also received radiation. Hence, among 39 genetically confirmed translocation RCCs in our personal experience, six (15%) have arisen in patients who had received cytotoxic chemotherapy. Conclusion: Cytotoxic chemotherapy may predispose to the development of renal translocation carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=33645741110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645741110&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.04.4693

DO - 10.1200/JCO.2005.04.4693

M3 - Article

VL - 24

SP - 1529

EP - 1534

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -